Spero Therapeutics Stock Performance
| SPRO Stock | USD 1.42 0.02 1.39% |
The entity has a beta of 1.17, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Spero Therapeutics will likely underperform. Spero Therapeutics has an expected return of -0.11%. Please make sure to validate Spero Therapeutics sortino ratio, as well as the relationship between the semi variance and rate of daily change , to decide if Spero Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Spero Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
1 | Sale by Ankit Mahadevia of 63795 shares of Spero Therapeutics | 02/05/2024 |
2 | Spero Therapeutics exotic insider transaction detected | 02/23/2024 |
3 | Spero Therapeutics to Present at Cowens 44th Annual Healthcare Conference | 02/26/2024 |
4 | Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024 | 03/06/2024 |
5 | Spero Therapeutics, Inc. Held Back By Insufficient Growth Even After Shares Climb 27 | 03/12/2024 |
6 | Earnings call Spero Therapeutics reports solid 2023 financials, advances RD By Investing.com - Investing.com | 03/14/2024 |
7 | Spero Therapeutics, Inc. Q4 2023 Earnings Call Transcript | 03/15/2024 |
8 | Spero Therapeutics Inc has fallen 2.23 percent Monday In Premarket Trading - InvestorsObserver | 03/18/2024 |
9 | Disposition of 8000 shares by Ankit Mahadevia of Spero Therapeutics at 14.5833 subject to Rule 16b-3 | 03/25/2024 |
10 | Spero Therapeutics Stock Passes Above 200-Day Moving Average of 1.40 - Defense World | 04/12/2024 |
11 | Spero Therapeutics Delivers On Game Plan To Create Shareholder Value - Seeking Alpha | 04/23/2024 |
| Begin Period Cash Flow | 109.1 M |
Spero |
Spero Therapeutics Relative Risk vs. Return Landscape
If you would invest 157.00 in Spero Therapeutics on January 26, 2024 and sell it today you would lose (15.00) from holding Spero Therapeutics or give up 9.55% of portfolio value over 90 days. Spero Therapeutics is currently does not generate positive expected returns and assumes 3.3276% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than Spero, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Spero Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Spero Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Spero Therapeutics, and traders can use it to determine the average amount a Spero Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0323
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SPRO |
Estimated Market Risk
| 3.33 actual daily | 29 71% of assets are more volatile |
Expected Return
| -0.11 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Spero Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Spero Therapeutics by adding Spero Therapeutics to a well-diversified portfolio.
Spero Therapeutics Fundamentals Growth
Spero Stock prices reflect investors' perceptions of the future prospects and financial health of Spero Therapeutics, and Spero Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Spero Stock performance.
| Return On Equity | 0.25 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.69 % | ||||
| Current Valuation | 6.51 M | ||||
| Shares Outstanding | 53.89 M | ||||
| Price To Earning | 81.20 X | ||||
| Price To Book | 0.83 X | ||||
| Price To Sales | 0.85 X | ||||
| Revenue | 96.73 M | ||||
| Gross Profit | (42.11 M) | ||||
| EBITDA | 20.11 M | ||||
| Net Income | 22.81 M | ||||
| Cash And Equivalents | 45.4 M | ||||
| Cash Per Share | 1.29 X | ||||
| Total Debt | 5.54 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 3.65 X | ||||
| Book Value Per Share | 2.02 X | ||||
| Cash Flow From Operations | (32.99 M) | ||||
| Earnings Per Share | 0.43 X | ||||
| Market Capitalization | 77.22 M | ||||
| Total Asset | 182.39 M | ||||
| Retained Earnings | (391.07 M) | ||||
| Working Capital | 94.06 M | ||||
| Current Asset | 7.3 M | ||||
| Current Liabilities | 6.04 M | ||||
About Spero Therapeutics Performance
To evaluate Spero Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Spero Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Spero Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Spero Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Spero's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.001 | 0 | |
| Return On Tangible Assets | 0.13 | 0.13 | |
| Return On Capital Employed | 0.14 | 0.14 | |
| Return On Assets | 0.13 | 0.13 | |
| Return On Equity | 0.21 | 0.22 |
Things to note about Spero Therapeutics performance evaluation
Checking the ongoing alerts about Spero Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Spero Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Spero Therapeutics generated a negative expected return over the last 90 days | |
| Spero Therapeutics may become a speculative penny stock | |
| Spero Therapeutics has high historical volatility and very poor performance | |
| Spero Therapeutics is unlikely to experience financial distress in the next 2 years | |
| Spero Therapeutics currently holds about 45.4 M in cash with (32.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29. | |
| Roughly 20.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Spero Therapeutics Delivers On Game Plan To Create Shareholder Value - Seeking Alpha |
- Analyzing Spero Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Spero Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Spero Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Spero Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Spero Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Spero Therapeutics' stock. These opinions can provide insight into Spero Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Spero Stock analysis
When running Spero Therapeutics' price analysis, check to measure Spero Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spero Therapeutics is operating at the current time. Most of Spero Therapeutics' value examination focuses on studying past and present price action to predict the probability of Spero Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spero Therapeutics' price. Additionally, you may evaluate how the addition of Spero Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is Spero Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.753 | Earnings Share 0.43 | Revenue Per Share 1.969 | Quarterly Revenue Growth 0.55 | Return On Assets 0.109 |
The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.